Latest Insider Transactions at Edgewise Therapeutics, Inc. (EWTX)
This section provides a real-time view of insider transactions for Edgewise Therapeutics, Inc. (EWTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Edgewise Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Edgewise Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 11
2021
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,270
-0.83%
|
$22,860
$18.02 P/Share
|
|
Oct 08
2021
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,902
-3.73%
|
$106,236
$18.15 P/Share
|
|
Oct 07
2021
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
13,018
-7.6%
|
$234,324
$18.56 P/Share
|
|
Oct 06
2021
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,108
-1.22%
|
$37,944
$18.03 P/Share
|
|
Oct 05
2021
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,404
-3.02%
|
$97,272
$18.26 P/Share
|
|
Oct 04
2021
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
100
-0.06%
|
$1,800
$18.0 P/Share
|
|
Oct 01
2021
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
274
-0.15%
|
$4,932
$18.0 P/Share
|
|
Sep 29
2021
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
11,844
-3.11%
|
$201,348
$17.15 P/Share
|
|
Sep 28
2021
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
14,610
-7.11%
|
$248,370
$17.3 P/Share
|
|
Sep 27
2021
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
11,611
-2.67%
|
$208,998
$18.23 P/Share
|
|
Sep 24
2021
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,100
-8.47%
|
$361,800
$18.16 P/Share
|
|
Sep 23
2021
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
26,835
-5.17%
|
$483,030
$18.88 P/Share
|
|
Mar 30
2021
|
Peter A. Thompson |
BUY
Open market or private purchase
|
Indirect |
359,375
+7.54%
|
$5,750,000
$16.0 P/Share
|
|
Mar 30
2021
|
Peter A. Thompson |
BUY
Conversion of derivative security
|
Indirect |
13,002,760
+49.69%
|
-
|
|
Mar 30
2021
|
Jonathan D Root |
BUY
Open market or private purchase
|
Direct |
15,625
+50.0%
|
$250,000
$16.0 P/Share
|
|
Mar 30
2021
|
Jonathan D Root |
BUY
Conversion of derivative security
|
Indirect |
3,473,543
+50.0%
|
-
|
|
Mar 30
2021
|
Novo Holdings > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
625,000
+10.06%
|
$10,000,000
$16.0 P/Share
|
|
Mar 30
2021
|
Novo Holdings > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
4,962,207
+50.0%
|
-
|
|
Mar 30
2021
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
359,375
+7.54%
|
$5,750,000
$16.0 P/Share
|
|
Mar 30
2021
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
13,002,760
+49.69%
|
-
|
|
Mar 30
2021
|
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
681,812
+50.0%
|
-
|
|
Mar 30
2021
|
James E Flynn > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
625,000
+13.71%
|
$10,000,000
$16.0 P/Share
|
|
Mar 30
2021
|
James E Flynn > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,308,137
+30.92%
|
-
|